The downgrade from Outperform to In-Line by a prominent analyst suggests a shift in the expected performance of Amylyx Pharma's stock. While not a direct negative, it indicates a more cautious stance on the company's near-term growth prospects or stock price performance. This could lead to a neutral or slightly negative investor sentiment in the short term.